Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Glioblastoma
Interventions: Trans Sodium Crocetinate plus SOC, Standard of Care (SOC); Drug · Other
Lead sponsor: Diffusion Pharmaceuticals Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 13
States / cities: Irvine, California • Redwood City, California • Santa Monica, California + 10 more

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Carvedilol, Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Not listed
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 86
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 71 more

Conditions: Asthma
Interventions: Benralizumab, Placebo; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 17
States / cities: Los Angeles, California • Rolling Hills Estates, California • Clearwater, Florida + 14 more

Conditions: Ankle Sprain
Interventions: Esflurbiprofen Hydrogel Patch; Drug
Lead sponsor: Teikoku Seiyaku Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Idiopathic Gastroparesis, Diabetic Gastroparesis, Gastroparesis
Interventions: Tradipitant, Placebo, Open Label Tradipitant; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 979 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 36
States / cities: Birmingham, Alabama • Peoria, Arizona • Little Rock, Arkansas + 30 more

Conditions: Cystic Fibrosis
Interventions: N91115; Drug
Lead sponsor: Nivalis Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 19
States / cities: Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 15 more

Conditions: Trichotillomania
Interventions: Habit Reversal Training; Behavioral
Lead sponsor: University of South Florida; Other
Eligibility: 7 Years to 17 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Laparoscopic Surgery
Interventions: Fentanyl, Labetalol, Esmolol; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cognitive Function
Interventions: Placebo Control Form 1, Clarity Active Study Product 1.1 Usage, Placebo Control Form 2, Clarity Active Study Product 2.1 Usage, Placebo Control Form 3, Clarity Active Study Product 3.1 Usage, Clarity Active Study Product 3.2 Usage, Placebo Control Form 4, Clarity Active Study Product 4.1 Usage, Placebo Control Form 5, Clarity Active Study Product 5.1 Usage, Clarity Active Study Product 5.2 Usage, Placebo Control Form 6, Clarity Active Study Product 6.1 Usage, Placebo Control 6.1.0, Clarity Active Study Product 6.1.1 Usage, Clarity Active Study Product 6.1.2 Usage; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years to 105 Years
Enrollment: 4,794 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Rheumatoid Arthritis
Interventions: Veltuzumab; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: La Mesa, California • Los Angeles, California • Upland, California + 5 more

Conditions: Moderate to Severe Allergic Asthma
Interventions: CYT003, Placebo; Biological
Lead sponsor: Cytos Biotechnology AG; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 21
States / cities: Los Angeles, Huntington Beach, San Jose, California • Walnut Creek, San Diego, Riverside, Fountain Valley, California • Colorado Springs, Denver, Colorado + 18 more

Conditions: Systemic Lupus Erythematosus
Interventions: Deucravacitinib, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 48
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 42 more

Conditions: NAD, NAD+ Levels in the Blood
Interventions: Qualia NAD⁺ version 1, Qualia NAD⁺ version 2, Qualia NAD⁺ version 3, Placebo; Dietary Supplement
Lead sponsor: Qualia Life Sciences; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Carlsbad, California

Conditions: Healthy
Interventions: azelaic acid pre-foam formulation, Vehicle pre-foam formulation, Water, Sodium lauryl sulfate; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Sleep
Interventions: Fruit/Honey drink, Placebo; Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 60 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Ulcerative Colitis
Interventions: Ontamalimab, Placebo; Drug · Other
Lead sponsor: Shire; Industry
Eligibility: 16 Years to 81 Years
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 94
States / cities: Mesa, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 80 more

Conditions: Venous Leg Ulcer
Interventions: EscharEx (5% EX-02 formulation), Gel Vehicle, Non-surgical standard of care (NSSOC); Drug
Lead sponsor: MediWound Ltd; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 21
States / cities: Carlsbad, California • Fresno, California • Los Angeles, California + 17 more

Conditions: Primary IgA Nephropathy
Interventions: Nefecon, Placebo oral capsule; Drug
Lead sponsor: Calliditas Therapeutics AB; Industry
Eligibility: 18 Years and older
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 34
States / cities: Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 28 more

Conditions: Breast Cancer, Colon Cancer, Neuropathy
Interventions: topical menthol, placebo lotion; Drug
Lead sponsor: Columbia University; Other
Eligibility: 21 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Musculoskeletal Disease
Interventions: Acceptance and Committment Therapy; Behavioral
Lead sponsor: University of New Hampshire; Other
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Durham, New Hampshire

Conditions: Alopecia Areata
Interventions: PF-06651600 Induction Dose, PF-06651600 Maintenance Dose #1, PF-06651600 Maintenance Dose #2, PF-06651600 Maintenance Dose #3, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 718 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 46
States / cities: Birmingham, Alabama • Beverly Hills, California • Irvine, California + 25 more

Conditions: Acne Vulgaris
Interventions: Adapalene, Differin®, Placebo; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 20
States / cities: Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 15 more

Conditions: Insomnia
Interventions: PD 0200390, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 682 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 71
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 57 more

Conditions: Alzheimer Disease
Interventions: Placebo, SAM-531 1.5 mg, SAM-531 3.0 mg, SAM-531 5.0 mg, Donepezil; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 526 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 37
States / cities: Phoenix, Arizona • Costa Mesa, California • Fresno, California + 28 more

Search by objective public record fields.

Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors

Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma

Proof-of-concept Study of NSAID Hydrogel Patch in Treatment of Acute Pain

Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis

Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation

Habit Reversal Training for Children and Adolescents With Trichotillomania

Labetalol and Esmolol: Vital Signs and Post Operative Pain Management

Radicle Clarity 24: A Study of Health and Wellness Products on Cognitive Function and Related Health Outcomes

VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis

CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma

A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

Comparison of Three Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels

21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation

Addressing Sleep Problems in Older Adults

An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis

A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers

Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy

Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy

Acceptance and Commitment Therapy, a Mindfulness-Based Approach for Treatment of Chronic Musculoskeletal Pain

PF-06651600 for the Treatment of Alopecia Areata

Bioequivalence of Adapalene Topical Gel in Patients With Acne Vulgaris

A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Outpatient Trial Of PD 0200390 In Adults With Primary Insomnia

Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease